ZBIO (Zenas Bio) Net Profit

ZBIO (Zenas Biopharma) - company brandmark

This Zenas Biopharma Inc (ZBIO) price chart illustrates profit dynamics, which currently stand at -0.48. The business relies on an asset-light management model: scientific research is conducted in the US and China, while production is outsourced to contractors. Demand for such drugs is independent of market cycles, as growth is driven by successful clinical trials. This reinforces the status of Zenas Biopharma Inc (ZBIO) as a promising industry leader.

ZBIO (Zenas Biopharma Inc) Net Profit history from 09/14/2024 to 10/31/2026

Analytical breakdowns and data insights for company Zenas Biopharma (ZBIO)

- price and consensus price forecast:
Stock Quotes Zenas Corp|ZBIO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Zenas Corp|ZBIO - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Zenas Biopharma|ZBIO - Book Capitalization|Market Capitalization to Book Value zenasbio.com|ZBIO - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Zenas Biopharma Inc|ZBIO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Zenas Bio|ZBIO - Company Total Debt|Debts to Book Capitalization Zenas Corp|ZBIO - Company Long-Term Debt|Company Short-Term Indebtedness Zenas Biopharma|Immediate Liquidity zenasbio.com
- net income and valuation multiples indicators:
ZBIO - Net Income
Summary company analysis:Zenas Biopharma Inc
Core merchandise of Zenas Biopharma, Inc.

Zenas Biopharma Inc (ZBIO) maintains a strong position in the immunology sector thanks to unique patents for the therapy of autoimmune pathologies. This indicator captures the actual cash balance after deducting all operating expenses and taxes. By analyzing the company's net income, an investor separates the real efficiency of R&D centers from management's accounting adjustments. This chart's dynamics allow for the rapid identification of profitability peaks from intellectual property. The steady growth of this metric confirms the long-term viability of the biopharmaceutical model.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN: Net Income|Profit After Tax PHAR|NKTR: Net Profit|Company Net Income upstreambio.com (UPB)|Company Net Income Immunome|Company Profit GOSS (Gossamer Bio Inc)|Net Profit KALV|Net Profit Septerna Pharma (SEPN)|Company Net Income Pieris Pharmaceuticals PVLA|Net Financial Result savarapharma.com (SVRA)|RIGL: Net Income|Final Profit ANAB (AnaptysBio Inc)|ATXS: Net Profit|ENGN (enGene Corp) - Company Net Income|RAPT (RAPT Therapeutics, Inc.) - Net Profit|Aerovate (JBIO) - Net Financial Result|Company Net Income Aclaris Therapeutics, Inc. (ACRS)|KYTX - Company Net Income|Company Net Income Tiziana Life Sciences PLC TLSA|CABA (Cabaletta Bio Inc) - Profit After Tax|Ventyx Biosciences - Net Profit|Final Profit THTX (theratech.com)|AVTX: Net Profit|Eledon Pharmaceuticals Inc. (ELDN) - Net Profit|Company Net Income Agenus Inc|CLYM: Final Profit|Company Net Income Zura Bio Limited (ZURA)|Net Income atyrpharma.com ATYR|Net Profit ADAG (Adagene Inc.)|Net Profit ImageneBio IMA|STTK: Net Income|Final Profit EQ (Equillium, Inc.)|CNTB: Net Profit|IMUX - Net Financial Result|Company Net Income Atara Biotherapeutics, Inc.|Company Profit IFRX (InflaRx GmbH)|Net Profit XFOR|Net Income adicetbio.com ACET|Celularity - Net Income|INMB (inmunebio.com) - Profit After Tax|Barinthus Biotherapeutics plc - Net Profit|KZR: Company Net Income|SABS: Net Profit|AKTX - Net Financial Result|Company Net Income Enlivex Therapeutics Ltd|Company Net Income Q32 Bio Corp QTTB|Company Net Income GeoVax (GOVX)|EDSA: Profit After Tax|Net Profit IBIO (iBio Corp)|Final Profit CARM|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|Aptevo Therapeutics Inc. - Final Profit|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Net Profit GRI|Net Profit xortx.com (XRTX)|Vyome Holdings - Net Income|Final Profit REVB|Indaptus - Net Profit|Net Financial Result BiondVax Pharmaceuticals SCNI|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Income IGMS (IGM Biosciences, Inc.)|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP: Company Profit|Third Harmonic Bio, Inc. - Net Profit